Supplementary Figures




Figure S1. scRNA-seq of TAMs identifies distinct polarization states within the tumor microenvironment. (A) Representative gating strategy for live (7AAD⁻) TAMs for sorting using the indicated surface markers from enzyme-dispersed *MMTV-PYMT* tumors used in scRNA-seq sample preparation analyzed in Fig. 1 and 2. (B) UMAP plots of the 9,039 TAMs sequenced using the 10X Genomics' Chromium platform across n=3 tumors displaying the expression of marker genes used to isolate TAM single cells in (A). (C) Heatmap showing top differentially expressed genes within each TAM cluster shown in Fig.1b, selected genes for each cluster are highlighted to the right of the heatmap. (D,E) Gene scores across all TAM clusters for proliferation (D) and MHCII associated genes (E). Box and whisker plots, the boxes show median and upper and lower quartiles and whiskers shows the largest value no more than 1.5*IQR of the respective upper and lower hinges, outliers beyond the end of the whisker are plotted as individual dots.




Figure S2. Trajectory analysis of scRNA-seq of TAMs reveals polarization-specific transcription factors and cytokine signatures associated with transcriptomic state. (A) Diffusion component (DC) plot showing single cells colored by pseudotime value for each distinct trajectory predicted by *Slingshot* trajectory analysis. Cells that are not associated with a given trajectory are greyed out. (B) Heatmap of selected genes varying significantly across trajectory. Single cells (columns) are arranged left to right by pseudotime value within their labeled trajectories, branching points are indicated beneath the heatmap. (C-E) Heatmaps representing chemokine, cytokine and complement factor genes (C), transcription factor genes (D) and additional chemokine, cytokine and complement receptor genes (E) that vary significantly across the predicted *Slingshot* trajectories.




Figure S3. Liposomes are specifically taken up by a PvTAM subset of TAM. (A-B) Representative histograms showing Dil-containing liposome uptake (red filled histogram) against PBS-filled liposome treated mice (open black line histogram) in CD90⁺ CAF and CD31⁺ endothelial cells in the CD45⁻ gate of enzyme-dispersed tumors from *MMTV-PyMT* mice treated as shown in Fig. 2J and assessed using flow cytometry, representative of n=3 mice (A). Proportion of live (7AAD⁻) gated tumor-resident phagocytic populations with detectable Dil uptake as assessed using flow cytometry (n=4 mice) (B). (C-E) Tumor bearing *MMTV-PyMT* mice treated with control PBS-filled liposomes (Cntrl-lip) or clodronate-filled liposomes (Clod-lip) using the treatment regimen shown in Fig. 3A, showing the percentage change in mouse weight over the course of the experiment (C), representative gating strategy for identifying different tumour-resident leukocyte populations (D), and number of distinct CD31⁺ endothelial vessel elements as assessed using immunofluorescence analysis stained frozen tissue sections (a total of n=12 sections, across n=6 mice per condition) (E). Bar charts represent mean and the dots show individual data points from individual tumors and mice. * P<0.05, ** P<0.01.




Figure S4. CD34^{+/-} CAF subsets are transcriptionally distinct and conserved across other murine models of cancer. (A-C) Bulk RNA-seg of the CD34^{+/-}CAF subsets, showing PCA plot of the bulk-sequenced CAF populations showing the difference in CAF transcriptome (A), differentially expressed genes between CD34^{+/-} CAF populations (B) and significantly upregulated GO terms based on differentially expressed genes of the two CAF subsets (**C**), across n=5 tumors and mice. (**D**) Representative confocal image of frozen MMTV-PyMT tumor sections showing DAPI (nuclei; blue), and antibody staining against CD31 (magenta), αSMA (red), desmin (green) and αSMA/desmin co-localization (yellow). Representative of multiple sections from n=4 tumors and mice. Scale bar represents 100µm. (E-F) Representative histogram of live (7AAD) CD90⁺CD34 CAFs gated using flow cytometry in a representative enzyme-dispersed MMTV-PyMT tumor; histogram shows surface staining for PDGFR\$ or NG2 as indicated (blue shaded) against that of the isotype control (open) (E), or gated live (7AAD-) CD90+CD34- NG2hi CAFs showing surface staining for PDGFRα and PDGFRβ as indicated (light blue shaded) against that of the isotype control (open). (G-H) Mice were injected with the indicated tumor cells and when tumors reached 1500mm³ they were enzyme-dispersed and analyzed by flow cytometry for the abundance of live (7AAD⁻) CD45⁻CD31⁻CD90⁺ CAFs (**G**) and the relative proportions of CD34⁺ and CD34⁻ CAFs (H) across n= 5-6 mice per model. Bar charts represent mean and error bars s.d., dots show individual data points from individual tumors and mice.




Figure S5. A αSMA⁺ CAF signature correlates with *PDGFC* expression in human breast cancer (**A**) The number of total potential ligand and receptor interactions identified per bulk RNA-sequenced cell type that participate in paracrine and autocrine signaling networks in the perivascular niche. (**B**) *Pdgfc* mRNA expression relative to the housekeeping gene *Actb* in FACS-sorted tumor cells (CD45⁻CD31⁻CD90⁻; n=6) and Lyve-1⁺ TAMs (n=3). (**C**) Normalized log2 RNA-seq counts for the TCGA-BRCA dataset for the αSMA^{hi} CAF gene signature in non-malignant breast tissue (n=112) and primary breast carcinoma tissue (n=1,093). (**D**) Scatterplot of αSMA⁺ CAF gene signature score (x axis) and *PDGFC* (y axis) (Pearson's r = 0.547, p < 0.0001) (left) or *PDGFA* (y-axis) (Pearson's r = 0.286 p < 0.0001) (right) from the TCGA-BRCA RNA-seq dataset, n=1,093. Box and whisker plots, the boxes show median and upper and lower quartiles and whiskers shows the largest value no more than 1.5*IQR of the respective upper and lower hinges, outliers beyond the end of the whisker are plotted as individual dots. Bar charts represent mean, error bars represent s.e.m. ***** *P*<0.0001.